Zacks: Brokerages Anticipate Atara Biotherapeutics Inc (ATRA) Will Announce Earnings of -$1.18 Per Share

Share on StockTwits

Analysts expect that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings per share of ($1.18) for the current quarter, according to Zacks. Zero analysts have made estimates for Atara Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($1.17) and the lowest estimate coming in at ($1.18). Atara Biotherapeutics posted earnings per share of ($1.02) in the same quarter last year, which would indicate a negative year-over-year growth rate of 15.7%. The business is scheduled to announce its next earnings results on Thursday, November 8th.

On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.58) per share for the current year, with EPS estimates ranging from ($4.59) to ($4.58). For the next financial year, analysts expect that the firm will post earnings of ($5.12) per share, with EPS estimates ranging from ($5.19) to ($5.05). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.17).

Several research firms recently commented on ATRA. BidaskClub downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Friday. Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 3rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $45.00 price objective on shares of Atara Biotherapeutics in a research report on Friday, August 3rd. Citigroup lowered their price objective on Atara Biotherapeutics from $25.00 to $23.00 and set a “sell” rating on the stock in a research report on Monday, June 11th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $70.00 price objective on shares of Atara Biotherapeutics in a research report on Tuesday, May 8th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $43.17.

In related news, insider Joe Newell sold 1,500 shares of the company’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $37.74, for a total transaction of $56,610.00. Following the completion of the sale, the insider now directly owns 33,358 shares in the company, valued at approximately $1,258,930.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Isaac E. Ciechanover sold 8,800 shares of the company’s stock in a transaction on Tuesday, May 22nd. The stock was sold at an average price of $51.74, for a total value of $455,312.00. Following the sale, the chief executive officer now owns 812,613 shares of the company’s stock, valued at $42,044,596.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 169,400 shares of company stock worth $7,301,767. Corporate insiders own 10.60% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Riverhead Capital Management LLC purchased a new stake in Atara Biotherapeutics in the 1st quarter valued at approximately $100,000. SG Americas Securities LLC purchased a new stake in Atara Biotherapeutics in the 1st quarter valued at approximately $107,000. Great West Life Assurance Co. Can lifted its stake in Atara Biotherapeutics by 100.1% in the 2nd quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 1,655 shares in the last quarter. Bank of Montreal Can purchased a new stake in Atara Biotherapeutics in the 2nd quarter valued at approximately $180,000. Finally, Highland Private Wealth Management purchased a new stake in Atara Biotherapeutics in the 2nd quarter valued at approximately $202,000. Hedge funds and other institutional investors own 98.58% of the company’s stock.

Atara Biotherapeutics traded up $0.65, hitting $38.10, during trading hours on Friday, according to MarketBeat. The company’s stock had a trading volume of 229,898 shares, compared to its average volume of 436,390. Atara Biotherapeutics has a 12 month low of $12.65 and a 12 month high of $54.45. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -9.53 and a beta of 2.55.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Read More: Average Daily Trade Volume – What It Means In Stock Trading

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Recent Analysts’ Ratings Updates for Hellofresh
Recent Analysts’ Ratings Updates for Hellofresh
Fabrinet  Stock Rating Lowered by Needham & Company LLC
Fabrinet Stock Rating Lowered by Needham & Company LLC
Avanos Medical  Lifted to Outperform at Raymond James
Avanos Medical Lifted to Outperform at Raymond James
ASLAN PHARMACEUTICALS ADR REP 5’s  “Buy” Rating Reaffirmed at HC Wainwright
ASLAN PHARMACEUTICALS ADR REP 5’s “Buy” Rating Reaffirmed at HC Wainwright
Phore Hits Market Capitalization of $8.38 Million
Phore Hits Market Capitalization of $8.38 Million
Reviewing Timberland Bancorp  & First Connecticut Bancorp
Reviewing Timberland Bancorp & First Connecticut Bancorp


Leave a Reply

© 2006-2018 Ticker Report. Google+.